CRNA secures NOK 620 million funding, touts circVec gains
Circio Holding ASA said circVec delivered up to 60x improved gene expression in vivo, with next-gen targeting 200x, alongside NOK 620 million in funding to support R&D expansion and collaborations.
CircVec technology delivered up to 60x improved gene expression in vivo, while next-generation targeting reached 200x. The company said it secured NOK 620 million in funding to support R&D expansion and collaborations, and said the financing reduces financial risk through 2030. Based on Circio Holding ASA [CRNA] Q2 2026 audio transcript.